ASH 2009

Rituximab bindet als therapeutischer Antikörper gezielt an das Molekül CD20 auf der Oberfläche von B-Zellen - und zieht diese dadurch aus dem Verkehr

Roche is presenting updated results of the pivotal phase III study, CLL8 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

The randomized CLL8 trial examines whether patients with previously untreated CLL live longer when they receive MabThera/Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy rather than FC alone. Initial results of the CLL8 trial – showing that patients remained disease-free for longer on MabThera/Rituxan-FC than on FC alone - were presented ASH in 2008. The new updated results of the CLL8 trial, which will feature in an oral presentation on Monday 7 December, are based on a longer median follow-up time than the initial results presented in 2008.

Here you will find the latest Roche news from the conference as well as supporting information.